The CRO transition is unlikely to affect Vera's regulatory strategy or near-term stock performance. Monitor for any changes in regulatory submission timelines or pipeline updates in subsequent filings.
VERA drugs
VERA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 9 $42.45entry
- T+1 · 4mo ago −1.06%α −1.49% · $42.00
- T+5 · 4mo ago −7.84%α −7.71% · $39.12
- T+20 · 3mo ago −24.57%α −26.81% · $32.02
- T+60 · 7w ago −28.34%α −29.97% · $30.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vera Therapeutics announced the transition of Chief Regulatory Officer William Turner to Special Advisor for Regulatory Affairs, effective August 3, 2026, with Nancy Bowman, M.D., Ph.D., succeeding him as CRO. This is a routine, orderly leadership change with a named successor, carrying no material operational or financial implications.
Key Facts
- William Turner steps down as Chief Regulatory Officer, transitions to Special Advisor for Regulatory Affairs effective August 3, 2026.
- Nancy Bowman, M.D., Ph.D., appointed as the new Chief Regulatory Officer, effective August 3, 2026.
- Orderly succession with both outgoing and incoming roles clearly defined.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-299165 |
| Document: 0001193125-26-299165-index-headers.html | 0001193125-26-299165 |
| Document: 0001193125-26-299165-index.html | 0001193125-26-299165 |
| Document: 0001193125-26-299165.txt | 0001193125-26-299165 |
Track record
25 reports on VERA
13 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 14 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers